Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 405

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance

Open access
Beltran, Himisha, Hruszkewycz, Andrew, Scher, Howard I., Hildesheim, Jeffrey, Isaacs, Jennifer, Yu, Evan Y., Kelly, Kathleen, Lin, Daniel, Dicker, Adam, Arnold, Julia, Hecht, Toby, Wicha, Max, Sears, Rosalie, Rowley, David, White, Richard, Gulley, James L., Lee, John, Diaz Meco, Maria, Small, Eric J., Shen, Michael, Knudsen, Karen, Goodrich, David W., Lotan, Tamara, Zoubeidi, Amina, Sawyers, Charles L., Rudin, Charles M., Loda, Massimo, Thompson, Timothy, Rubin, Mark A., Tawab-Amiri, Abdul, Dahut, William, Nelson, Peter S.·2019·Clinical Cancer Research

Abstract

Lineage plasticity has emerged as an important mechanism of treatment resistance in prostate cancer. Treatment-refractory prostate cancers are increasingly associated with loss of luminal prostate markers, and in many cases induction of developmental programs, stem cell–like phenotypes, and neuroendocrine/neuronal features. Clinically, lineage plasticity may manifest as low PSA progression, resistance to androgen receptor (AR) pathway inhibitors, and sometimes small cell/neuroendocrine pathologic features observed on metastatic biopsy. This mechanism is not restricted to prostate cancer as other malignancies also demonstrate lineage plasticity during resistance to targeted therapies. At present, there is no established therapeutic approach for patients with advanced prostate cancer developing lineage plasticity or small cell neuroendocrine prostate cancer (NEPC) due to knowledge gaps in the underlying biology. Few clinical trials address questions in this space, and the outlook for patients remains poor. To move forward, urgently needed are: (i) a fundamental understanding of how lineage plasticity occurs and how it can best be defined; (ii) the temporal contribution and cooperation of emerging drivers; (iii) preclinical models that recapitulate biology of the disease and the recognized phenotypes; (iv) identification of therapeutic targets; and (v) novel trial designs dedicated to the entity as it is defined. This Perspective represents a consensus arising from the NCI Workshop on Lineage Plasticity and Androgen Receptor-Independent Prostate Cancer. We focus on the critical questions underlying lineage plasticity and AR-independent prostate cancer, outline knowledge and resource gaps, and identify strategies to facilitate future collaborative clinical translational and basic studies in this space.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-19-1423

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 46 references

Cited by

See all 405

Metadata

Authors
Beltran, H., Hruszkewycz, A., Scher, H. I., Hildesheim, J., Isaacs, J., Yu, E. Y., Kelly, K., Lin, D., Dicker, A., Arnold, J., Hecht, T., Wicha, M., Sears, R., Rowley, D., White, R., Gulley, J. L., Lee, J., Diaz Meco, M., Small, E. J., Shen, M., Knudsen, K., Goodrich, D. W., Lotan, T., Zoubeidi, A., Sawyers, C. L., Rudin, C. M., Loda, M., Thompson, T., Rubin, M. A., Tawab-Amiri, A., Dahut, W., & Nelson, P. S.
Venue
Clinical Cancer Research
Published
2019-12-01
Volume
25
Issue
23
Pages
6916-6924
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2964673115
Cited by
405
References
46
FWCI
24.38
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-19-1423
The paper
Beltran, H., Hruszkewycz, A., Scher, H. I., Hildesheim, J., Isaacs, J., Yu, E. Y., Kelly, K., Lin, D., Dicker, A., Arnold, J., Hecht, T., Wicha, M., Sears, R., Rowley, D., White, R., Gulley, J. L., Lee, J., Diaz Meco, M., Small, E. J., . . . Nelson, P. S. (2019). The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-19-1423

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.